Elevation Pharmaceuticals has presented positive results from a Phase 2a study of its glycopyrrolate inhalation solution in patients with moderate to severe COPD at the European Respiratory Society (ERS) meeting in Amsterdam. If Elevation can bring the formulation, known as EP-101, to market, it would be the first long-acting muscarinic antagonist (LAMA) available for nebulization.
According to the company, EP-101 demonstrated statistically significant improvement in lung function as measured by FEV1 versus placebo at all doses in a randomized, double blind, placebo controlled, cross-over, dose-ranging study. The glycopyrrolate inhalation solution, delivered by a PARI investigational eFlow nebulizer system, was also tolerated well and had a comparable safety profile to the placebo.
Bill Gerhart, Elevation’s President and CEO commented, “We are very encouraged by the outcomes of this study in COPD. These positive results bring us closer to achieving our goal of validating a new standard of care for COPD that significantly improves patient compliance and clinical outcomes.” The company has already initiated a Phase 2b study called GOLDEN-1 (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer).
Read the Elevation press release.
Read the poster abstract.
